Protocol Ledger

NCT03385655 · Phase II · ACTIVE NOT RECRUITING

Prostate Cancer Biomarker Enrichment and Treatment Selection

Interventional Phase II clinical trial protocol NCT03385655 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-01 Enrollment: 200 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03385655
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03385655
Protocol FieldVerified Registry Value
NCT IdentifierNCT03385655
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment200 participants (ACTUAL)
Registered Start Date2018-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03385655
Hospital Research SiteLocationSite Profile
Cross Cancer InstituteEdmonton, CanadaOpen Hospital Dossier ->
University Health NetworkToronto, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI